CHARACTERISTICS AND PROGNOSIS OF HORMONE RECEPTOR POSITIVE AND HER2 NEGATIVE RECURRENT BREAST CANCER PATIENTS RECEIVING POSTOPERATIVE AROMATASE INHIBITOR

被引：0
|
作者：
Mayumi, Ishida [1 ]
Akiko, Igawa [1 ]
Akihiro, Saruwatari [1 ]
Masahiro, Oikawa [1 ]
Chinami, Koga [1 ]
Sumiko, Nishimura [1 ]
Yumiko, Koi [1 ]
Sayuri, Akiyoshi [1 ]
Yoshiaki, Nakamura [1 ]
Shinji, Ohno [1 ]
机构：
[1] Kyushu Natl Canc Ctr, Fukuoka, Japan
来源：
BREAST | 2013年 / 22卷
关键词：
D O I：
10.1016/S0960-9776(13)70098-5
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S48 / S49
页数：2
相关论文
共 50 条
  • [41] Survival analysis of HER2 receptor negative and HER2 receptor low breast cancer patients at a Philippine hospital
    Arenos, C. C.
    San Juan, M.
    Lim, S.
    Lominoque, A.
    Reveldez, I.
    Sison-DImaano, A.
    Pangandaman, N.
    Tatoy, V.
    Uy, T.
    ANNALS OF ONCOLOGY, 2024, 35 : S1390 - S1390
  • [42] Molecular Characteristics and Prognosis of Triple Negative Breast Cancer Stratified by HER2 Status
    Yang, Xia
    LABORATORY INVESTIGATION, 2024, 104 (03) : S318 - S319
  • [43] Hormone receptor status might be a determinant for HER2 loss after HER2-targeted treatment in HER2 positive breast cancer patients
    Altundag, Kadri
    JOURNAL OF BUON, 2019, 24 (05): : 2206 - 2206
  • [44] Prospect for Application of PARP Inhibitor in Patients with HER2 Negative Breast Cancer
    Shao, Nan
    Shi, Yawei
    Yu, Liang
    Ye, Runyi
    Shan, Zhen
    Zhang, Zhanqiang
    Zhang, Yunjian
    Lin, Ying
    INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES, 2019, 15 (05): : 962 - 972
  • [45] Prognosis of metastatic breast cancer subtypes: the hormone receptor/HER2 positive subtype is associated with the most favorable outcome
    Tjan-Heijnen, V. C. G.
    Lobbezoo, D. J. A.
    van Kampen, R. J. W.
    Voogd, A. C.
    Dercksen, M. W.
    van den Berkmortel, F.
    Smilde, T. J.
    van de Wouw, A. J.
    Peters, F. P. J.
    van Riel, J. M. G. H.
    Peters, N. A. J. B.
    Borm, G. F.
    CANCER RESEARCH, 2012, 72
  • [46] Unfavourable Prognosis in PT1b HER2 Positive and Triple Negative Breast Cancer Patients
    Vaccaro, A.
    Ciancola, F.
    Vici, P.
    Sperduti, I.
    Moscetti, L.
    Pizzuti, L.
    Di Seri, M.
    Ruggeri, E. M.
    Giampaolo, M. A.
    Gamucci, T.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S386 - S386
  • [47] Moderate HER2 expression as a prognostic factor in hormone receptor positive breast cancer
    Eggemann, Holm
    Ignatov, Tanja
    Burger, Elke
    Kantelhardt, Eva Johanna
    Fettke, Franziska
    Thomssen, Christoph
    Costa, Serban Dan
    Ignatov, Atanas
    ENDOCRINE-RELATED CANCER, 2015, 22 (05) : 725 - 733
  • [48] TrastuzumabIn HER2 and Hormone Receptor Co-Positive Metastatic Breast Cancer
    Jennifer S. Orman
    Caroline M. Perry
    Drugs, 2007, 67 : 2781 - 2789
  • [49] HER2 and hormone receptor-positive breast cancer—blocking the right target
    Javier Cortés
    Cristina Saura
    Meritxell Bellet
    Eva Muñoz-Couselo
    Natalia Ramírez-Merino
    Virginia Calvo
    Jose Pérez
    María Vidal
    Nature Reviews Clinical Oncology, 2011, 8 : 307 - 311
  • [50] Systemic Treatment Decision Making for Patients with Stage I and II, Hormone Receptor Positive, Her2/neu Negative Breast Cancer
    Zhu, X.
    Graham, N.
    Paquet, L.
    Dent, S.
    Song, X.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : S74 - S74
12345